Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments
Z Yuan, Y Li, S Zhang, X Wang, H Dou, X Yu, Z Zhang… - Molecular cancer, 2023 - Springer
The malignant tumor is a multi-etiological, systemic and complex disease characterized by
uncontrolled cell proliferation and distant metastasis. Anticancer treatments including …
uncontrolled cell proliferation and distant metastasis. Anticancer treatments including …
Diffuse large B-cell lymphoma
LH Sehn, G Salles - New England Journal of Medicine, 2021 - Mass Medical Soc
Diffuse Large B-Cell Lymphoma DLBCL, an aggressive cancer, accounts for about 30% of
all lymphomas. Empirical combination chemotherapy cures about 65% of patients initially …
all lymphomas. Empirical combination chemotherapy cures about 65% of patients initially …
Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma
Axicabtagene ciloleucel (axi-cel) is an anti-CD19 chimeric antigen receptor (CAR) T cell
therapy approved for relapsed/refractory large B cell lymphoma (LBCL) and has treatment …
therapy approved for relapsed/refractory large B cell lymphoma (LBCL) and has treatment …
Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL
In diffuse large B cell lymphoma (DLBCL), tumors belonging to the ABC but not GCB gene
expression subgroup rely upon chronic active B cell receptor signaling for viability, a …
expression subgroup rely upon chronic active B cell receptor signaling for viability, a …
A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications
GW Wright, JD Phelan, ZA Coulibaly, S Roulland… - Cancer cell, 2020 - cell.com
The development of precision medicine approaches for diffuse large B cell lymphoma
(DLBCL) is confounded by its pronounced genetic, phenotypic, and clinical heterogeneity …
(DLBCL) is confounded by its pronounced genetic, phenotypic, and clinical heterogeneity …
Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma
Chimeric antigen receptor (CAR) T-cell therapy has emerged as an option for
relapsed/refractory aggressive B-cell lymphomas that have failed 2 lines of therapy. Failures …
relapsed/refractory aggressive B-cell lymphomas that have failed 2 lines of therapy. Failures …
Inferring gene expression from cell-free DNA fragmentation profiles
Profiling of circulating tumor DNA (ctDNA) in the bloodstream shows promise for
noninvasive cancer detection. Chromatin fragmentation features have previously been …
noninvasive cancer detection. Chromatin fragmentation features have previously been …
Determining cell type abundance and expression from bulk tissues with digital cytometry
Single-cell RNA-sequencing has emerged as a powerful technique for characterizing
cellular heterogeneity, but it is currently impractical on large sample cohorts and cannot be …
cellular heterogeneity, but it is currently impractical on large sample cohorts and cannot be …
BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies
A Alu, H Lei, X Han, Y Wei, X Wei - Journal of Hematology & Oncology, 2022 - Springer
Bruton's tyrosine kinase (BTK) is an essential component of multiple signaling pathways that
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …
regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising …
The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma
Biological heterogeneity in diffuse large B cell lymphoma (DLBCL) is partly driven by cell-of-
origin subtypes and associated genomic lesions, but also by diverse cell types and cell …
origin subtypes and associated genomic lesions, but also by diverse cell types and cell …